India is a hugely important market for Randox Laboratories and has been for many years now. This trend has continued into 2018 and so far, this year has proved to be nothing short of exceptional for us as a company.
As a country and a market, India is close to the hearts of everyone involved with Randox Laboratories, emphasized by the existence of our manufacturing plant in Bangalore. Our rapid growth in the Indian market is something we are proud of and we will strive to nurture the relationship between Randox Laboratories and our customers while continuing to grow as a company in the hope of offering the best diagnostic solutions to laboratories – regardless of their size or financial capabilities.
A major bonus for us in the Indian market this year is the success of our homocysteine reagent (HCY). To date, this reagent has generated a lot of interest and continues to be purchased nationwide. For those who may be unaware, homocysteine is a thio-containing amino acid produced by the intracellular demethylation of methionine. Elevated levels of homocysteine are more common in women than in men and are associated with a wide array of illnesses including cardiovascular disease (CVD), colon cancer, pregnancy complications, and birth defects.
As CVD is the leading cause of death globally, extending the cardiology and lipid testing panel will aid in the identification of CVD risk factors, both in primary and secondary risk categories; and as such, provide the necessary tools to prevent and reduce the risk. Randox offer a comprehensive cardiology and lipid product profile which includes: superior performance assays such as, Lp(a) and homocysteine; unique assays such as H-FABP, sdLDL-C, HDL2/3; and novel biomarkers such as adiponectin.
The remainder of 2018 will be very much the same as what we have done in the past 8 to 9 months in India. We will continue to meet with laboratories and help with their requirements in whatever way possible throughout the remainder of 2018 and as part of our market strategy for 2019.
With regards to new products, Randox Laboratories invests heavily into research and development (R&D) and therefore our new products are always unique. We would advise all laboratory staff to look out for new Randox products in the market; however, one product we would raise everyone’s attention to is our revolutionary Biiochip Array Technology (BAT). The Biochip from Randox is capable of simultaneous multi-analyte diagnostic testing within the fields of clinical research and drugs of abuse testing. This technology works through combining a panel of related assays on a single biochip with a single set of reagents, controls, and calibrators. Currently the Biochip holds up to 49 tests but has the potential to significantly increase this number. An extensive range of Biochip panels are available, including clinical, research, toxicology, and molecular arrays, each of these are optimized to provide the best performance.
Randox Laboratories are very excited for 2019 – continuing to improve our relations in India while providing first class customer service is of paramount importance to the company and this is something we strive toward regardless of the time of year.
Additionally, Randox Laboratories will be significantly increasing the presence in the Indian market throughout 2019. Over the course of the year, Randox will attend multiple exhibitions across the country, showcasing vast product portfolio which includes, quality controls, external quality assessment, reagents, and clinical chemistry analyzers among others. We always find these shows a great place to meet new and existing customers and we look forward to meeting you there.
Lastly, Randox Laboratories would like to thank all customers for the continued support over the years and we look forward to continuing or beginning our relationship with you.